Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0 - 12/10/12

Doi : 10.1016/j.jaad.2012.02.010

Alice P. Chen, MD ^a, Ann Setser, BSN, MEd ^b, Milan J. Anadkat, MD ^c, Jonathan Cotliar, MD ^d, Elise A. Olsen, MD ^e, Benjamin C. Garden, BA ^f, Mario E. Lacouture, MD ^f,^⁎
^a Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
^b Investigational Drug Branch, National Institutes of Health/National Cancer Institute/Cancer Therapy Evaluation Program, Rockville, Maryland
^c Division of Dermatology, Washington University School of Medicine, St Louis, Missouri
^d Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
^e Department of Medicine, Divisions of Dermatology and Oncology, Duke University Medical Center, Durham, North Carolina
^f Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence to: Mario E. Lacouture, MD, Memorial Sloan-Kettering Cancer Center, Suite 228, 160 E 53 St, New York, NY 10022.

Abstract

Dermatologic adverse events to cancer therapies have become more prevalent and may to lead to dose modifications or discontinuation of life-saving or prolonging treatments. This has resulted in a new collaboration between oncologists and dermatologists, which requires accurate cataloging and grading of side effects. The Common Terminology Criteria for Adverse Events Version 4.0 is a descriptive terminology and grading system that can be used for uniform reporting of adverse events. A proper understanding of this standardized classification system is essential for dermatologists to properly communicate with all physicians caring for patients with cancer.

Le texte complet de cet article est disponible en PDF.

Key words : adverse events, cancer treatment, Common Terminology Criteria for Adverse Events, drug reactions, grading system, side effects

Abbreviations used : ADL, AE, BSA, CTCAE, CTCAEv4, EGFR, MASCC, MedDRA, NCI, SOC

Plan

	Supported by US National Institutes of Health; Dr Lacouture receives funding from a Zell Scholarship from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and a Dermatology Foundation Career Development Award.
	Disclosure: Dr Cotliar serves on an advisory board for Amgen. Dr Anadkat is a speaker and consultant for ImClone and BMS; and a speaker for Genentech, Eisai, and Hana Biosciences. Dr Lacouture has worked as a consultant for ImClone, Bristol-Myers Squibb, GSK, Amgen, Merck, Vertex, Roche, Pfizer, OSI Pharmaceuticals Inc, and Genentech. Dr Chen, Ms Setser, Dr Olsen, and Mr Garden have no conflicts of interest to declare.
	Reprints not available from the authors.